January 10, 2018
As the new year gets into full swing, we at AVAC look forward to assessing, untangling, confronting and calling on all of us to commit to HIV prevention in all its complexity. Building on the advocacy agenda we lay out in AVAC Report 2017, and a corresponding December episode of our Px Pulse podcast, our January episode expands on what we’re looking forward to in the year ahead.
- Major new vaccine and long-acting injectable PrEP trials are launching.
- The dapivirine ring is under regulatory review, and could be the world’s next biomedical prevention option since oral PrEP.
- Recent findings from the Rakai Community Cohort Study in Uganda confirmed what models predicted—bringing combinations of existing interventions, such as voluntary medical male circumcision and antiretroviral treatment, to scale slashes new HIV diagnoses. How can we leverage these findings to maximize prevention at the global level?
- What will advocates need to do this year to prepare for results—anticipated in 2019—of a key trial called ECHO that’s looking at whether contraceptive methods affect HIV risk?